SCHEMBL5336980

SCHEMBL5336980

CC(=O)OCc1ccc(C(c2ccccc2)(c2ccccc2)c2ncc[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
GPR84 Q9NQS5 2/20 0.37
CYP19A1 P11511 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
RAB9A P51151 2/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
VCP P55072 1/20 0.35
CASR P41180 1/20 0.35
POLB P06746 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11740459 0.77 ACSS2 (0.38) ALDH1A1CYP19A1CHRM2CHRM4CHRM5
Trityl Imidazole SCHEMBL1572623 0.77 MTOR (0.45) ALDH1A1CYP19A1TSHRMEN1KMT2A
SCHEMBL11838904 0.76 ALDH1A1 (0.40) ALDH1A1L3MBTL1RAB9ATSHRCASP3
SCHEMBL5738213 0.74 NISCH (0.43) ALDH1A1CYP19A1RAB9ATSHRMEN1
SCHEMBL10896794 0.74 SMN1; SMN2 (0.48) CYP19A1L3MBTL1KMT2ACYP3A4
Trityl Imidazole SCHEMBL7622943 0.73 TAAR1 (0.36) CYP19A1TSHR
SCHEMBL11089506 0.73 MTOR (0.45) ALDH1A1CYP19A1TSHRMEN1KMT2A
SCHEMBL6410046 0.73 ALDH1A1 (0.45) ALDH1A1GPR84MEN1KMT2ACHRM2
SCHEMBL9669719 0.73 TAAR1 (0.36) CYP19A1TSHRKMT2A
SCHEMBL6571082 0.73 CYP19A1 (0.39) CYP19A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537114-B8 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS NOVARTIS AG (CH) 2007-10-03 EP disclosed
EP-1537114-A1 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS Novartis AG (CH) 2005-06-08 EP disclosed
EP-1090011-A4 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 2005-04-06 EP disclosed
WO-2004014914-A1 ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS NOVARTIS AG (CH) 2004-02-19 WO disclosed
EP-1090011-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2001-04-11 EP disclosed
WO-2001017992-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-03-15 WO disclosed
WO-2000001701-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-01-13 WO disclosed